Skip to main content
. 2017 Mar 20;28(6):1294–1301. doi: 10.1093/annonc/mdx112

Figure 3.

Figure 3.

(A) Progression-free survival after anti-EGFR plus irinotecan-based therapy in the second or third-line setting in RAS wild-type metastatic colorectal cancer patients according to method of RAS mutation detection (SoC tumor tissue at baseline =50 or ctDNA plasma before therapy =47). (B) Survival in metastatic setting according to RAS mutant allele fraction by ctDNA plasma. MAF of 0.1 corresponds to a percentage of mutant alleles of 10%. SoC, standard of care.